Health
First in Human Study with Novel Antisense Oligonucleotide – EurekAlert
A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans.
IMAGE: focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression.
view more
Credit: Mary Ann Liebert, Inc., publishers
New Rochelle, NY, August 11, 2020–A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans. Inhibition of miR-92a has shown beneficial effects in animal models, including improved vascularization after myocar…
-
Noosa News19 hours agoDangerous storm pounds south-east Queensland with giant hail, blackouts and widespread damage
-
Noosa News22 hours agoBruce Highway fatal: Grandmother’s heartbreak as daughter and granddaughter killed in Queensland truck crash
-
Noosa News22 hours agoPassenger footage of Sea World helicopters colliding
-
General10 hours agoXi Jinping tells Donald Trump Taiwan’s ‘return to China’ is key to international post-war order